权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

AIBP and Endothelial Function

AIBP 和内皮功能

基本信息

批准号：
8885205
负责人：
Yury Miller
金额：
$ 51.56万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8885205
关键词：
Address Adhesions Animal Model Aorta Apolipoprotein A-I Apoptosis Arterial Fatty Streak Atherosclerosis Autophagocytosis Binding Proteins Blood Vessels Cardiovascular Diseases Cardiovascular system Cell Adhesion Molecules Cell membrane Cell model Cell physiology Cells Cholesterol Consensus Development Diet Disease Dyslipidemias Endothelial Cells Event Foam Cells Future High Density Lipoproteins Human Inflammation Inflammatory Inflammatory Response Infusion procedures Knockout Mice Lead Leukocytes Lipids Lipoproteins Low-Density Lipoproteins Measures Mediating Membrane Lipids Membrane Microdomains Modeling Modification Morbidity - disease rate Mus Myocardial Infarction Nature Pathology Patients Peptides Peripheral arterial disease Plasma Play Population Prevention Process Property Protein Deficiency Proteins Publishing Raisins Receptor Signaling Recombinants Recruitment Activity Role Sampling Signal Pathway Smooth Muscle Myocytes Stroke Surface Testing Therapeutic Therapeutic Effect Tissues United States Vascular Permeabilities Zebrafish atheroprotective base cardiovascular disorder risk cardiovascular disorder therapy chemokine cytokine endothelial dysfunction feeding improved in vivo macrophage monocyte mortality mouse model novel oxidized low density lipoprotein paracrine prevent protein expression public health relevance research study transcytosis vascular inflammation

项目摘要

DESCRIPTION (provided by applicant): Inflammation and lipid accumulation in the vascular wall constitute critical events in initiation and progression of cardiovascular disease, manifested in myocardial infarction and stroke in more than a half of the US population. Activated endothelial cells (EC) secrete chemokines and express adhesion molecules to recruit leukocytes to the vascular wall. Oxidized LDL and dysfunctional HDL play a major role in EC-mediated inflammation, whereas functional HDL preserves the EC integrity and prevents inflammatory responses. One of the major mechanisms by which HDL exerts its protective function is cholesterol efflux from the plasma membrane of EC. We discovered that apoA-I binding protein (AIBP) significantly improves HDL function by accelerating cholesterol efflux from EC. AIBP is a secreted protein and its effect on EC is paracrine and non-cell autonomous. These findings open the possibility of using AIBP or AIBP-derived peptides as a therapy to improve the cholesterol efflux function of HDL and thereby prevent and/or reverse vascular pathology. Here we propose to test the hypothesis that AIBP reduces EC inflammatory responses via modulation of cholesterol efflux and lipid rafts. We will test this hypothesis in cellular models as well as in aorta explants, by measuring expression of cytokines and adhesion molecules, probing relevant signaling pathways, detecting ROS, apoptosis and autophagy, and assessing LDL transcytosis and monocyte adhesion. Further, we will determine effects of systemic and tissue-specific AIBP deficiency on endothelial function. We have developed Aibp LoxP and Aibp knockout mice, which are viable and fertile. AIBP expression has been detected in macrophages and vascular smooth muscle cells (VSMC) of mouse atherosclerotic lesions. Thus, we propose that AIBP secreted by macrophages and/or VSMC protects aortic EC and that deletion of Aibp in these cells will lead to exacerbated EC inflammatory responses and increased atherosclerosis burden. We also hypothesize that, conversely, raising AIBP levels will improve endothelial function and reduce inflammation. The hypothesis will be tested in vivo with mouse and zebrafish animal models and ex vivo with human plasma samples obtained from patients with dyslipidemia and/or cardiovascular disease (CVD). In a hypercholesterolemic zebrafish model, we expect that conditional expression of Aibp will reduce vascular lipid accumulation, foam cell formation, membrane lipid order in EC, and vascular permeability. In a hypercholesterolemic mouse model, we expect that infusion of recombinant AIBP, alone or in combination with apoA-I, will reduce EC inflammation and atherosclerosis. In addition, human plasma and HDL isolated from CVD patients will be supplemented with recombinant AIBP and tested for their effect on monocyte adhesion to EC. We expect that AIBP will improve protective properties of dysfunctional HDL. Results of these experiments, if positive, will facilitate future development of AIBP-based therapeutic applications.